May 15, 2012 Program
Guest speaker – Steve Dickman: CEO & Founder CBT Advisors
Steve Dickman is CEO of CBT Advisors (www.cbtadvisors.com), a life sciences consulting firm in Cambridge, Massachusetts. CBT Advisors works on product positioning and corporate strategy; communications strategy, media relations and fund-raising materials; and market analysis based on research and expert interviews. Clients include public and private pharma, biotech companies, granting agencies, academic institutions as well as life science venture funds.
Mr. Dickman publishes an industry blog, Boston Biotech Watch (http://bostonbiotechwatch.com), that tracks industry, VC and technology trends.
Before founding CBT Advisors in 2003, Mr. Dickman spent four years in venture capital with TVM Capital. There, Mr. Dickman’s deals included Sirna Therapeutics, sold to Merck in 2006 for $1.1 billion. Earlier, he was a Knight Science Journalism Fellow at MIT, a freelance contributor to The Economist, Discover, Science, GEO and Die Zeit and the founding bureau chief for Nature in Munich, Germany. Fluent in German, Mr. Dickman received his biochemistry degree cum laude from Princeton University.
CytoSorbents Corporation – Phillip P. Chan, MD, PhD: Chief Executive Officer and President
CytoSorbents Corporation (OTCBB: CTSO) is a U.S. publicly-traded, critical care-focused, therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses such as infection and sepsis, trauma, burns, lung injury, pancreatitis and surgical complications. Its flagship product, CytoSorb®, is approved as a first-in-class extracorporeal cytokine filter in the European Union and is now generating early revenue. It is designed to treat “cytokine storm” and reduce the systemic inflammatory response syndrome (SIRS) that leads to organ failure. HemoDefend is another technology in advanced development designed to purify the millions of transfused blood products administered each year to prevent transfusion reactions and reduce the adverse events associated with “old” blood. CytoSorbents technology is protected by 29 issued patents and multiple applications pending.
Phillip Chan, Ph.D. is the CEO and President of CytoSorbents Corporation. Prior to CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for NJTC Venture Fund. He was responsible for numerous investments in therapeutics, medical devices and diagnostics. Dr. Chan also co-founded Andrew Technologies, a venture-backed medical device company developing novel, advanced surgical instruments. Dr. Chan is a Board-certified internal medicine physician with a strong background in clinical medicine and research, having completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. Dr. Chan received his MD/PhD from Yale University School of Medicine and his BS in cell and molecular biology from Cornell University.
Biofrontera AG – Professor Herrmann Lübbert, PhD, Chief Executive Officer
Prof. Hermann Lübbert, PhD, born in 1956, is founder (1997) of Biofrontera AG. He studied Biology in his native city of Cologne, where he completed a PhD in 1984. After eight years of academic research at the University of Cologne and the California Institute of Technology (USA), he spent ten years gaining experience in global research management at Sandoz and Novartis Pharma AG, prior to establishing Biofrontera in 1997. Prof. Lübbert was awarded the habilitation at the ETH (Eidgenössische Technische Hochschule) Zürich and holds the chair of Animal Physiology at Ruhr-University Bochum.